Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to
NEW YORK, July 29, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transaction may contain terms that could limit superior competing offers.Shareholders are encouraged to
NEW YORK, July 24, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is
All-share transaction creating a combined company to operate as Scancell advancing a pipeline of targeted, off-the-shelf, active immunotherapiesCombined company to be listed on Nasdaq, in addition to Scancell’s existing
Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the
Company Urges Shareholders to Follow ISS' Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP),
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote "FOR" BOTH of Neuphoria's Nominees on the WHITE Proxy Card BURLINGTON,
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the
Confirms Receipt of Unsolicited Indication of Interest and Director Nominations from Lynx1 Master Fund LP No Stockholder Action Required at This Time BURLINGTON, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Neuphoria
BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric
